CR20180003A - Métodos de modulación de moléculas de vigilancia de adn citosólicas - Google Patents

Métodos de modulación de moléculas de vigilancia de adn citosólicas

Info

Publication number
CR20180003A
CR20180003A CR20180003A CR20180003A CR20180003A CR 20180003 A CR20180003 A CR 20180003A CR 20180003 A CR20180003 A CR 20180003A CR 20180003 A CR20180003 A CR 20180003A CR 20180003 A CR20180003 A CR 20180003A
Authority
CR
Costa Rica
Prior art keywords
methods
modulation
molecules
cytosolic dna
dna surveillance
Prior art date
Application number
CR20180003A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Ilg
Jason Nickell
Christian Weiss
Alberth Abraham
Daniel Keil
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CR20180003A publication Critical patent/CR20180003A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20180003A 2015-06-26 2016-06-23 Métodos de modulación de moléculas de vigilancia de adn citosólicas CR20180003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (1)

Publication Number Publication Date
CR20180003A true CR20180003A (es) 2018-03-20

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180003A CR20180003A (es) 2015-06-26 2016-06-23 Métodos de modulación de moléculas de vigilancia de adn citosólicas

Country Status (22)

Country Link
US (1) US20190233825A1 (enExample)
EP (1) EP3313376A2 (enExample)
JP (1) JP2018518511A (enExample)
KR (1) KR20180021874A (enExample)
CN (1) CN108472255A (enExample)
AR (1) AR105160A1 (enExample)
AU (1) AU2016282879A1 (enExample)
BR (1) BR112017028121A2 (enExample)
CA (1) CA2990526A1 (enExample)
CL (1) CL2017003373A1 (enExample)
CR (1) CR20180003A (enExample)
DO (1) DOP2017000313A (enExample)
HK (1) HK1256128A1 (enExample)
IL (1) IL256264A (enExample)
MX (1) MX2017017141A (enExample)
PE (1) PE20181208A1 (enExample)
PH (1) PH12017502413A1 (enExample)
RU (1) RU2018102915A (enExample)
SG (1) SG10201913395VA (enExample)
TW (1) TW201710509A (enExample)
UY (1) UY36756A (enExample)
WO (1) WO2016207314A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
NZ750181A (en) 2016-07-26 2023-02-24 Bayer Animal Health Gmbh Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
EP1167378B1 (en) * 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1326969B1 (en) * 2000-09-25 2009-04-15 Genetronics, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
DK1789559T3 (en) * 2004-08-13 2015-08-24 Univ Pennsylvania Methods to construct vaccines with no antibiotic resistance
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失dnaワクチン
PT2992899T (pt) * 2009-05-14 2020-09-21 Bayer Ip Gmbh Resposta imunitária reforçada em espécies aviárias
UY33821A (es) * 2010-12-22 2012-07-31 Bayer Animal Health Gmbh Respuesta inmune potenciada en la especie bovina
CA2834442A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
BR112016019837A2 (pt) * 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores

Also Published As

Publication number Publication date
EP3313376A2 (en) 2018-05-02
BR112017028121A2 (pt) 2018-09-04
DOP2017000313A (es) 2018-02-28
CA2990526A1 (en) 2016-12-29
IL256264A (en) 2018-02-28
CN108472255A (zh) 2018-08-31
PH12017502413A1 (en) 2018-06-25
AU2016282879A1 (en) 2018-01-18
RU2018102915A3 (enExample) 2019-12-05
AR105160A1 (es) 2017-09-13
WO2016207314A3 (en) 2017-02-09
WO2016207314A2 (en) 2016-12-29
RU2018102915A (ru) 2019-07-29
HK1256128A1 (zh) 2019-09-13
MX2017017141A (es) 2018-03-09
US20190233825A1 (en) 2019-08-01
UY36756A (es) 2017-01-31
JP2018518511A (ja) 2018-07-12
CL2017003373A1 (es) 2018-06-29
KR20180021874A (ko) 2018-03-05
PE20181208A1 (es) 2018-07-23
TW201710509A (zh) 2017-03-16
SG10201913395VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
MX376105B (es) Método para producir l-aminoacidos utilizando una bacteria alcalifílica.
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
MX375524B (es) Anticuerpos anti-axl.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201691374A1 (ru) Инсулин длительного действия и его применение
EP3547906A4 (en) SEMIOLOGY OF EPILEPSY ATTACKS INCLUDING MUSCLE SIGNALS COLLECTED FROM ELECTROENCEPHALOGRAPHY ELECTRODES
MX2021010460A (es) Metodo de tratamiento con tradipitant.
BR112016023494A2 (pt) método, aparelho e mídia legível por computador para gerar um conjunto de produtos ortopédicos recomendados.
DOP2017000313A (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
EP3602547C0 (en) TARGET SAMPLE GENERATION
EA201591720A1 (ru) Белки, специфические по отношению к baff и b7rp1, и их применение
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
EP3365321A4 (en) SOLABEGRON TWITTERION AND USES THEREOF
DK3144383T3 (da) Mikroorganisme af Corynebacterium-slægten til fremstilling af L-lysin og fremgangsmåde til fremstilling af L-lysin under anvendelse af denne
EP3862937C0 (en) GENERATION OF WEATHER FORECASTS USING HOTL SUPERVISION
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi